Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × OTHER_GOV × enzalutamide × Clear all

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

OTHER 26 INDUSTRY 12 OTHER_GOV 1 NIH 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Capecitabine 3 pembrolizumab 2 palbociclib 2 durvalumab 2 Oxaliplatin 2 Metformin 2 tremelimumab 1 trametinib 1 sintilimab 1 olaparib 1 nilotinib 1 nabiximols 1 lenvatinib 1 glasdegib 1 futibatinib 1 enzalutamide 1 dabrafenib 1 citric acid, ispaghula husk, sodium bicarbonate drug combination 1 ceritinib 1 capmatinib 1 capivasertib 1 avelumab 1 atezolizumab 1 anlotinib 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 abiraterone 1 Zoledronic Acid 1 Vi-siblin 1 Trastuzumab 1 Tamoxifen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00268476 2023-04-18

STAMPEDE

Medical Research Council

Phase 2/3 Active not recruiting

11,992 enrolled

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡